Edition:
United Kingdom

Strides Pharma Science Ltd (SRID.NS)

SRID.NS on National Stock Exchange of India

442.15INR
22 Mar 2019
Change (% chg)

-- (--)
Prev Close
Rs442.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,662,373
52-wk High
Rs718.50
52-wk Low
Rs333.30

Latest Key Developments (Source: Significant Developments)

India's Strides Pharma Science Dec-Qtr Consol Net Profit Rises
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Strides Pharma Science Ltd ::DEC QUARTER CONSOL NET PROFIT 2.93 BILLION RUPEES VERSUS PROFIT OF 854.8 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 285.5 MILLION RUPEES .DEC QUARTER CONSOL REVENUE FROM OPERATIONS 7.95 BILLION RUPEES VERSUS 7.49 BILLION RUPEES LAST YEAR.IN DEC QTR, CO HAD A GAIN OF 2.72 BLN RUPEES ON DISPOSAL OF ASSETS.SAYS STRIDES TO EXIT ARROW FOR A VALUE OF A$394 MILLION.SAYS ACQUISITION OF 80 PERCENT STAKE IN PHARMAPAR INC TO BUILD OUT CANADIAN OPERATIONS.ACQUISITION OF 100 PERCENT STAKE IN VENSUN PHARMACEUTICALS, INC. TO TAKE CONTROL OF THE PARTNERED PRODUCTS.TO CONVERT CO'S 50:50 JVS WITH VIVIMED TO 100% OWNERSHIP.CO TO SELL COMPLETE STAKE IN ARROW TO ENTITIES OWNED AND OPERATED BY DENNIS BASTAS, EXECUTIVE CHAIRMAN AND CO-FOUNDER OF ARROW.ARROW WILL MERGE WITH APOTEX TO CREATE THE NEW ENTITY ARROTEX.PROPOSED TRANSACTION ALLOWS STRIDES TO ENTER INTO A 10-YEAR PREFERRED SUPPLIER CONTRACT WITH THE MERGED ENTITY.TRANSACTION TO EXIT ARROW WOULD BE IMMEDIATELY EPS ACCRETIVE .WILL ALSO RETAIN ACCESS TO IP OF 140 PRODUCTS IN ARROW PORTFOLIO WITH FUNGIBILITY IN OTHER GLOBAL MARKETS.  Full Article

Strides Pharma Science Gets USFDA Approval For Lidocaine Ointment
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Strides Pharma Science Ltd ::SAYS RECEIVES USFDA APPROVAL FOR LIDOCAINE OINTMENT.  Full Article

Strides Pharma Science Says Unit Enters Into Strategic Partnership With SUDA Pharmaceuticals
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Strides Pharma Science Ltd ::STRIDES ENTERS INTO A STRATEGIC PARTNERSHIP WITH SUDA PHARMACEUTICALS FOR US MARKET.  Full Article

Strides Pharma Science Says Unit Got USFDA Nod For Potassium Chloride Extended Release Tablets
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Strides Pharma Science Ltd ::STRIDES PHARMA GLOBAL PTE. LTD SINGAPORE GOT USFDA NOD FOR POTASSIUM CHLORIDE EXTENDED RELEASE TABLETS.PRODUCT WILL BE MANUFACTURED AT CO'S FACILITY AT BANGALORE AND MARKETED BY STRIDES PHARMA INC. IN THE US MARKET.  Full Article

Strides Shasun Gets U.S. FDA Approval For Ibuprofen OTC Tablets
Monday, 2 Jul 2018 

July 2 (Reuters) - Strides Shasun Ltd ::SAYS CO GETS U.S. FDA APPROVAL FOR IBUPROFEN OTC TABLETS.  Full Article

Strides Shasun Gets USFDA Tentative Approval For Milnacipran Hydrochloride Tablets
Monday, 2 Jul 2018 

July 2 (Reuters) - Strides Shasun Ltd ::SAYS STRIDES SHASUN RECEIVES USFDA TENTATIVE APPROVAL FOR MILNACIPRAN HYDROCHLORIDE TABLETS.  Full Article

Strides Shasun Gets WHO Prequalification for Rectal Artesunate Product
Thursday, 21 Jun 2018 

June 21 (Reuters) - Strides Shasun Ltd ::SAYS CO'S RECTAL ARTESUNATE PRODUCT RECEIVES WHO PREQUALIFICATION.PREQUALIFICATION FOR RECTAL ARTESUNATE SUPPOSITORIES (RAS) FOR PRE-REFERRAL MANAGEMENT OF SEVERE MALARIA.  Full Article

Strides Shasun Appoints Arun Kumar As Group CEO And MD
Friday, 18 May 2018 

May 18 (Reuters) - Strides Shasun Ltd ::SAYS ARUN KUMAR TO BE GROUP CEO AND MANAGING DIRECTOR OF THE COMPANY .SAYS DEEPAK VAIDYA TO BE THE CHAIRMAN OF THE BOARD OF DIRECTORS OF THE COMPANY.  Full Article

India's Strides Shasun March-Qtr Consol Profit Rises Five-Fold
Friday, 18 May 2018 

May 18 (Reuters) - Strides Shasun Ltd ::MARCH QUARTER CONSOL NET PROFIT 5.68 BILLION RUPEES VERSUS PROFIT OF 1.12 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 6.64 BILLION RUPEES VERSUS 6.77 BILLION RUPEES LAST YEAR.  Full Article

India's Strides Shasun Gets U.S. FDA Nod For Cinacalcet Hydrochloride Tablets
Wednesday, 2 May 2018 

May 2 (Reuters) - Strides Shasun Ltd ::STRIDES SHASUN RECEIVES USFDA APPROVAL FOR CINACALCET HYDROCHLORIDE TABLETS.PRODUCT WILL BE MANUFACTURED AT CO'S ORAL DOSAGE FACILITY AT PUDUCHERRY.PRODUCT WILL BE MARKETED BY STRIDES PHARMA INC IN THE U.S. MARKET.  Full Article